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Introduction
Streptococcus pneumoniae infections are a major cause of illness 
and death with about 1.6 million cases of fatal pneumococcal 
disease occurring worldwide annually, mostly in infants and the 
elderly.41 Streptococcus pneumoniae can cause both non-invasive 
and invasive infections.1 In adults and elderly, non-invasive dis-
ease can manifest as pneumonia, whereas bacteremia and men-
ingitis are the most common invasive pneumococcal diseases.1 
Although, pneumococcal disease can affect all age groups, the 
elderly and immunocompromised are at highest risk from infec-
tion.2 Moreover, since the introduction of pneumococcal conju-
gate vaccination in children in 2000, the epidemiology of invasive 
pneumococcal disease (IPD) has changed with the reported bur-
den of IPD now highest in the elderly population. In the US, the 
annual incidence of IPD in those ≥65 years of age was recently 
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reported to be 40/100,000 versus 21/100,000 in children <5 
years of age.3 In Europe, there has been a similar shift of the bur-
den of pneumococcal disease to the elderly population.4 Elderly 
patients are more vulnerable to infections due to physiological 
changes associated with aging process, therefore, the risk of an 
individual to develop pneumonia rises as they grow older. On a 
yearly basis, approximately one out of twenty persons over the age 
of 85 will have one episode of pneumonia.5 While in most cases, 
the etiological diagnosis of CAP will not have been obtained, the 
results of a study by Johnstone and co-workers6 showed that in 
37% of the cases, Streptoccocus pneumoniae is the causative agent 
of bacterial pneumonia. In Latin America, S. pneumoniae was 
demonstrated to be also the most common pathogen implicated 
in adult CAP, accounting for 35% of cases.7 Consequently, mor-
tality due to pneumonia also rises with age. In a study on the 
burden of community acquired pneumonia (CAP) reported by 
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which has the largest population and the most developed economy 
(approximately 30% of the Brazilian GDP) of the Brazilian States. 
Currently, Sao Paulo State offers PPV23 for institutionalized 
elderly and those with underlying diseases. The aim of this study 
was to evaluate the health and economic benefits of the PPV23 
public funding to the general elderly population in Sao Paulo.
Results
Cost-effectiveness analyses. In the base case scenario where a 
routine PPV23 vaccination program is implemented in São Paulo 
State from age 60, vaccination markedly reduced the number of 
episodes of pneumococcal infections. With a cohort of 3,689,623 
individuals, the number of NBPP and BPP cases avoided after 
5 years due to pneumococcal vaccination was 12,469 and 2,967 
respectively. The number of life years gained (LYG) was 5,218.
The incremental costs related to implementation of PPV23 
program in elderly people in São Paulo State was: R$56.8, 
R$43.2 and R$-5.4 million respectively for scenario 1 using the 
costs paid by the Brazilian social security SUS, for scenario 2 
using the total costs of a public hospitalization, and for scenario 3 
taking into account the costs in a private hospital and the absen-
teeism costs (Table 1). The averted costs of pneumococcal infec-
tions outweighed the costs of a vaccination program in scenario 3. 
Consequently, the ICER related to a PPV23 vaccination program 
in São Paulo State in elderly varied according to the scenarios 
(Table 1): R$10,887 in scenario 1; R$8,281 in scenario 2 and 
cost-saving in scenario 3 suggesting a return on the investment.
Sensitivity analyses. In the univariate sensitivity analysis, we 
evaluated the individual effects of epidemiological and vaccina-
tion parameters on the cost-effectiveness of the vaccination strat-
egy using the minimum and the maximum of the inputs range 
(Tables 2–4). As the various inputs should have relatively the 
same impact on results in each scenario, the univariate sensitivity 
analysis was performed only on scenario 1 (SUS hospitalization 
costs). Factors having the greatest impact on ICER were the vac-
cine effectiveness against NBPP, the case-fatality rate of NBPP, 
and the incidence rates of NBPP (Fig. 3).
A probabilistic sensitivity analysis of the cost-effectiveness 
results using the range or standard deviation of each input (Tables 
2–4) is also shown as a cost-effectiveness plane in Figure 2. These 
results demonstrate that there is a 95% chance that the incremen-
tal cost per LYG is contained in the interval R$[6,273; 29,223] 
for scenario 1 (mean R$13,516); R$[-1,275; 24,653] for scenario 
2 (mean at R$10,357), and R$[-76,509; 22,373], for scenario 3 
(mean at -R$3,247).
Discussion
Cost-effectiveness evaluations, such as the one described here, are 
necessary to define population strategies and help decision mak-
ers to choose the most relevant options in term of cost/benefit 
ratio of immunization programs.
In view of the variety of healthcare systems that exist through-
out Brazil, the present analysis was performed from three differ-
ent scenarios. From the cost study performed in Sao Paulo State, 
Jackson et al.5 in 2004, 12.5% of the patients over 80 years-old 
admitted to hospital for pneumonia die while in the hospital.
Resistance of pneumococci to commonly used antimicrobi-
als is a serious and increasing problem worldwide, which com-
plicates the treatment of infection.8 Antibiotic-resistance causes 
an increase in treatment failures and medical costs. Lynch and 
Zhanel reported in 2009 that worldwide, 15–30% of S. pneu-
moniae strains are multidrug resistant (i.e., resistant to ≥3 classes 
of antibiotics). These investigators also reported that six sero-
types (6A, 6B, 9V, 14, 19F, 23F) account for >80% of penicil-
lin- or macrolide-resistant S. pneumoniae, worldwide.9 Moreover 
in the US, an increase in the isolation of antibiotic resistant 19A 
strains has been reported, a strain associated with increased inci-
dence of IPD.10 Effective immunization against S. pneumoniae is 
the most effective method to reduce the impact of pneumococcal 
infections, including those caused by antibiotic resistant strains. 
Therefore, physicians and policy-makers have high expectations 
concerning the value of pneumococcal vaccination of the adults 
and elderly.
Currently, the pneumococcal vaccine approved in adults is 
the 23-valent pneumococcal polysaccharide vaccine (PPV23). 
A growing number of national and international health bodies 
now recommend pneumococcal vaccination of elderly and at-risk 
groups. Indeed, PPV23 has been shown to be clinically effective 
in the reduction of the occurrence of both bacteremic pneumo-
coccal pneumonias (BPP) and non-bacteremic pneumococcal 
pneumonias (NBPP).11
The world’s population is progressively aging. This trend is 
also reflected in Brazilian population where both the proportion 
of the total population and the real number of elderly people (≥60 
years old) have significantly risen for the past few years. Brazilian 
national statistics data show that the population over 60 years has 
grown from 8.8% in 1998 to 11.1% in 2008, and should became 
the sixth largest elderly population in the world by 2020.
In Brazil, presently the public national immunization program 
recommends PPV23 only for institutionalized elderly, but there is 
no funding for this vaccination program. As a result, the PPV23 
coverage rate in Brazil is low. In fact, data from the Brazilian 
public health system indicate that only 160,508 doses were used 
in 2009, which represents a coverage rate of approximately 0.8% 
if we consider the total demography of adults aged more than 
60 in Brazil in 2009. In US, PPV23 has been recommended for 
all people aged ≥65 years since 1983 and totally financed, and 
data shows that the coverage increased from 14.1% in 1989 to 
60.1% in 2008.12 In the Latin America region, most countries 
recommend and finance PPV23 in the general elderly popula-
tion considering the health and economic benefit of PPV23. 
These countries include Argentina, Chile, Ecuador, El Salvador, 
Mexico, Uruguay, Panama and Venezuela.
To date there have been no cost-effectiveness studies of 
pneumococcal vaccination of the elderly conducted in Brazil. 
Therefore, as a response to the need to decrease the burden of 
pneumococcal disease in Brazil’s elderly population, we conducted 
a cost-effectiveness analysis of the PPV23 vaccination program in 
order to evaluate the medical and economic impact of a PPV23 
public funding. This analysis was conducted in Sao Paulo State, 
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diseases, vaccination with PPV23 is again more cost-effective 
or cost-saving compared to no vaccination strategy among the 
elderly, considering only direct medical costs.24-27 This economic 
benefit increases with age of elderly targeted and vaccination of 
all individuals above the age 65 years is comparable in terms of 
cost-effectiveness to many accepted health care interventions.27
The study’s limitations were related to the various inputs used. 
Firstly, in absence of specific local data, incidence and case-fatal-
ity rates were derived from international data. It is likely that 
the disease epidemiology and health service utilization might be 
different between US/Europe and Brazil because of differences 
in prevalent strains, antibiotic resistance within the populations, 
quality of health care and financial architecture of their respec-
tive health-care systems. However, the chosen values were dis-
cussed and accepted by local experts to ensure their consistency 
with the local epidemiology. Moreover, to be sure to not over-
estimate the impact of S. pneumoniae in Brazil, we used generally 
the most conservative value found. Epidemiological data related 
to pneumonia in Latin America was published just before the 
finalization of this manuscript.7 These local data were globally 
less conservative than those used in the base case and were all 
included in sensitivity analysis range. Using these data in the SUS 
base case scenario returned a cost-effectiveness ratio of R$9,709/
LYG. The second limitation is related to the disease costs used in 
the present analysis. The sample size used to calculate the costs of 
hospitalization may be considered a limitation. It is enough large 
for NBPP cost calculation (N = 173 and N = 163 for public and 
private hospital respectively) but too small for BPP (N = 12 and 
N = 17 for public and private hospital respectively). Larger stud-
ies including larger numbers of patients with BPP will be neces-
sary for confirmation. In addition, our analysis considered only 
the costs of hospitalization and not the outpatient costs and other 
costs related to pneumococcal infections such as transportation, 
diet, etc. Including these costs would increase the economic ben-
efit of PPV23 vaccination. Thirdly, vaccination costs concerned 
only vaccine price and transportation. Promotion costs to ensure 
a high coverage rate also would have been estimated.
three different costs of hospitalization appeared: the lowest cost 
was that paid by SUS (R$462 for NBPP and R$830 for BPP), the 
intermediate cost was the amount actually paid by the public hos-
pital (R$1,992 for NBPP and R$5,103 for BPP) and the highest 
was the cost of hospitalization in the private hospital (R$19,764 
for NBPP and R$33,320 for BPP). Evaluation of cost-effective-
ness ratios using the SUS and the public healthcare costs allowed 
coverage of the public perspective on the whole. In scenario 3, 
integrating larger costs (private hospitalization costs and absen-
teeism costs) allowed the inclusion of persons who used a private 
health care system, i.e., 46% of the total elderly population e.g., 
persons using a managed care organization.
In many developed countries, acceptable cost-effectiveness 
thresholds have been defined for planning healthcare policies. 
However, no such definition is available in Brazil, an emerging 
country facing limited healthcare resources. The World Health 
Organization (WHO) has suggested an acceptable cost-effective-
ness threshold as one that is less than three times the yearly gross 
domestic product (GDP) per capita and an excellent cost-effec-
tiveness threshold as one that is less than one times the yearly 
GDP per capita.13 In Brazil, where the yearly GDP per-capita 
was R$13,720 in 2007 14 at the time of the analysis, an interven-
tion with a cost-effectiveness of up to R$41,160 may therefore be 
considered as cost-effective by WHO standards. Consequently, 
in the present analysis, PPV23 vaccination program from age 
60 was either extremely cost-effective (inferior to R$13,720 for 
social security and public health care perspectives) or cost saving 
(for societal perspective), depending on the scenario considered. 
This evidence was in favor of a routine PPV23 vaccination pro-
gram that would be offered by the government to all adults 60 
years of age and older.
Using pessimistic values in deterministic sensitivity analyses, 
all ICER also were found to be below the WHO cost-effectiveness 
threshold of R$41,160 (3 times the GDP per capita). Specifically, 
the ratio with an effectiveness of PPV23 against NBPP at 0% was 
R$33,342 which is still under this limit. This means that even 
with no effectiveness against NBPP, a routine PPV23 vaccination 
program in elderly in Sao Paulo is a cost-effective option, which 
is in line with the other published studies in reference 15–17. 
In addition, in the probabilistic sensitivity analyses, taking into 
account all uncertainties around parameters and the thresholds 
of R$41,160, there were a probability of 99.8%, 100% and 100% 
that the funding of PPV23 vaccination is cost-effective compared 
to the current situation with no vaccination for scenarios 1, 2 and 3 
respectively. If we considered the threshold of R$13,720, the prob-
ability would decrease to 60.9%, 74.8% and 87% respectively.
Our results are consistent with those of numerous cost-effec-
tiveness analyses performed in US and Europe. As Postma et al.18 
concluded in their literature review published in 2003 on the basis 
of the international literature in the elderly, the cost-effectiveness 
for the prevention of invasive pneumococcal disease, consider-
ing only direct medical costs, varies from cost-saving to more 
than €30,000 per LYG or per QALY.15,19-23 These results would 
justify local implementation of a pneumococcal polysaccharide 
vaccination program from a pharmacoeconomic point of view. In 
studies concerning both invasive and non invasive pneumococcal 
Table 1. Base case results per perspective of the cost-effectiveness 
analysis of polysaccharide pneumococcal vaccination comparing the 
non-vaccinated (NV) and vaccinated (V) cohort
Scenario 1 Scenario 12 Scenario 13
NV V NV V NV V
Costs in million R$ 
cost of NBpp infections 9 8.1 38.7 34.8 198.4 178.6
cost of Bpp infections 6.4 4.4 39.6 27 141.4 96
Vaccination - 59.8 - 59.8 - 59.8
Cost reduction thanks to vaccination, in million R$  
(million US$, 1 US$ = R$ 17,955)
Incremental costs  
(no vaccination- 
vaccination)
56.8 43.2 -5.4
Cost effectiveness analysis
IceR (R$/LYG) 10,887 8,281 cost-saving
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analyses (with the most pessimistic incidence values for NBPP 
and BPP, ICER stayed cost-effective) and regarding a recent anal-
ysis performed in US that included this indirect effect.22
Within the Brazilian population aged more than 59 years, 
a large proportion is still economically active. Indeed 18.8% of 
people older than 60 years-old are still employed.31 For this rea-
son, the analysis undertaken from the societal perspective was 
relevant in Brazil. Prevention strategies such as vaccination are 
extremely important to maintain the economic activity of adults 
aged 60 and older to maintain functional independence with 
advancing age. The aging of the population increases health 
costs and elderly people with acute diseases often require more 
complex health examinations and treatments. Elderly patients 
admitted for longer treatments are also much more susceptible to 
functionality loss. Therefore, a patient with pneumococcal dis-
ease can become economically inactive and incur high expenses 
with the initial disease and any subsequent sequelae.
Methods
Model specification and parameters used for the analysis. A 
decision-analytic model was developed by Ezus Group (Lyon, 
France) to estimate the effectiveness and cost-effectiveness of a 
polysaccharide pneumococcal vaccination program in adult pop-
ulation (more than 18 years old) with a possibility to focus the 
Over the last decade, the importance and benefit of pneumo-
coccal polysaccharide vaccination in adults has been reviewed 
due to the decrease of pneumococcal incidence rate in countries 
with a high coverage rate of pneumococcal conjugate vaccines 
(PCV) in infants. Indeed, in the US, where the coverage rate of 
the 7-valent pneumococcal conjugate vaccine (PCV7) in children 
has achieved 80–90% over the last 6 years, herd immunity has 
globally led to a 38% decrease in the rate of IPD among elderly.28 
However, an increase of the incidence of IPD in adults and elderly 
caused by non-PCV serotypes has been noted in many settings 
(“serotype replacement”); these increases range from minimal 
to substantial29 and could reduce the benefits of the PCV vac-
cination.30 Subsequently, PPV23 is the only protection available 
against these non-PCV7 serotypes at this time. Our analysis did 
not take into account the diminution of pneumococcal infec-
tions incidence in adults that could result thanks to the use of the 
10-valent pneumococcal conjugate vaccine (PCV10), now rou-
tinely used in Brazil. The use of PCV10 in Brazil is recent and to 
date no herd immunity data are available. The future effect of a 
PCV10 program in Brazil will depend on coverage rates, serotype 
prevalence and serotype replacement inherent to PCV would not 
likely to be observed before the program is well established with a 
high vaccine coverage rate. However, even including an indirect 
effect of PCV, we can still expect cost-effectiveness results for 
PPV23 vaccination program regarding our univariate sensitivity 
Table 2. epidemiological data used in the model
Item Base case value Range Sources/Comments
NBpp incidence  
(per 100,000)
706 425–1099
ament et al. 2000;18 754 hospitalized cap per 100,000 person-years in 65+. 
NBpp incidence rate calculated using following assumptions: 
-40% of cap are pneumococcal pneumonia 
-80% of pneumococcal pneumonia are NBpp 
-NBpp and Bpp hospitalization rates in Brazil are 18.6% and 95.5% respectively 
Minimum and maximum values also from ament et al. 2000 18 (451 and 1,167 for 
incidence of hospitalized pneumonia in France and sweden respectively)
Bpp incidence (per 100,000) 54.5 24–85
WHO WeR 2008: IpD Range in 65+ in industrialized countries.41 Mean value  
calculated from the range
NBpp hospitalization rates 18.6% 10%–30%
Based on the assumption that the 
probability of hospitalization varies from 10% for 60–70 yo people to 30% for 
people more than 70 (mean weighted by sao paulo population size)
Bpp hospitalization rates 95.5% 90–100%
Vila-corcoles et al. 2006;37 found that 4.5% of IpD cases were not hospitalized 
(1/22 cases) in spain (hospitalization rate of 95.5%). 
Range assumed considering the severity of the disease.
NBpp case fatality rates 12.7% 3.6%–18%
Mean from Vila-corcoles 2009 (spain, 65+) 66 
Low value from Jackson 2004 (Us, 65+) {Jackson, 2004;6/id} 
High value from Luna 2000 (argentina, 18+) 43
Bpp case fatality rate 26.6% 11%–44%
Fedson and Musher in 2004; 1 reported an IpD cFR range from 11% to 44% 
(mean = 26.6%, 16 studies included) in elderly in developed countries  
Middleton 2008 42 reported an IpD cFR of 14.3% for 65–74 yo, 21% in 75–84 yo 
and 30.8% for 85+ yo in Us 
WHO WeR 2008 41 says that Bpp cFR may reach 30–40% in elderly and in indus-
trialized countries 
evers 2007 reported a mean IpD cFR on 10 european countries at 21% in 65+) 14
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effectiveness of PPV23 against invasive pneumococcal disease 
and therefore BPP is largely proven whereas the vaccine effective-
ness against NBPP is debatable.
• The patient can not develop a BPP and a NBPP in the same 
one year period. However, a patient with a BPP or NBPP event in 
one period can develop an event in a subsequent period.
• The event “Death due to other causes than BPP or NBPP” is 
independent of all events.
• Death of patients occurs uniformly over 1 year period.
• Every patient with a pneumococcal infection (BPP or NBPP) 
generates the same costs if they survived or not.
For each cohort, the number of life years experienced and the 
costs of pneumococcal infections were calculated and compared. 
To compare the costs and health consequences of PPV23 vacci-
nation versus non-vaccination, an incremental cost-effectiveness 
ratio (ICER) was estimated as the incremental cost per life year 
gained (LYG). Since no health utility data are available in Brazil, 
the quality-adjusted life year (QALY) due to vaccination was not 
evaluated. The concept and methodology of cost-utility analyses 
is not well established in Brazil, the evaluation of LYG can be 
considered an initial approach in the analysis of cost-utility.
analysis on an age-based or a risk-based program. This model also 
has been used in Turkey69 and Korea.33 Two identical cohorts, 
either vaccinated with the PPV23 or non-vaccinated (since the 
coverage rate in Brazil in this population is closed to zero), were 
designed to reflect the São Paulo State elderly population (≥60 
years old). Each cohort was followed during a 5-year period 
divided into 5 periods of 1 year to provide a conservative estimate 
of the total duration of PPV23 effectiveness. Infections due to 
S. pneumonia were classified as either BPP or NBPP, which com-
prise around 90% of pneumococcal-related outcomes that are 
preventable by PPV23 vaccination.1 The structure of the model is 
illustrated in Figure 1.
Model assumptions are described below:
• Individuals in the “vaccinated” group receive one dose of 
PPV23 at the beginning of year 1 according to vaccine coverage 
rate. They can receive a second dose at the beginning of year 6 
if revaccination is considered (not the case in the present study).
• For individuals vaccinated and immunized, the vaccine 
effectiveness decreases over the five periods.
• One person vaccinated and immunized against NBPP is 
automatically considered immunized against BPP. Indeed, the 
Table 3. Vaccination data used in the model
Item Base case value Range Sources/Comments
Vaccine effectiveness
against NBpp
21% 0–42%
Vila-corcoles, 2009 (42% in 50+ against NBpp);10 Vila-corcoles, 2006 (39% in 65+ 
against NBpp and 21% against all cap),37 Maruyama, 2010 (64% against pneumococ-
cal pneumonia and 45% against all cap in nursing home residents);55 Huss, 2009 
(11% in elderly and chronically ill patients against all cap from 11 RcT but high het-
erogeneity)54 
Vaccine effectiveness
against Bpp
64% 44–80%
Mooney, 2008 (61.70% in elderly);51 Vila-corcoles, 2010 (72% in 60+);47 Jackson, 2003 
(44% in 65+);52 Domingez, 2005 (70% in all elderly);50 shapiro, 1991 (46% to 80% in 
65+);53 Butler, 1993 (75% in 65+)48
Waning rate each year 10% 0–20%
sisk, 1997;38 smith, 2008;21 Middleton, 2008,42 Merito, 2007;23 postma, 2001;20  
shapiro, 1991;53 
Vaccination coverage rate 60% - Hypothesis in case of ppV-23 100% funding by public system for elderly
Vaccination cost R$27 = Us$15* -
Vaccine public price + vaccine transportation door to door = R$27 = Us$15 (from a 
public payer perspective)
*The 2008 mean exchange rate was used to reflect the monthly rate variation (1 UsD = 1.7955 BRL).
Table 4. cost of hospitalization in R$ per case (direct medical cost in standard police, public health care costs with indirect costs in italic, and private 
costs with indirect costs underlined)
Item Mean value SD Source/comment
Scenario 1 (i.e., Sistema único de saúde—SUS reimbursement package as defined by Brazilian Ministry of Health)
NBpp 462 293 Vigipneumo retrospective study in public Hospital sao paulo (Hsp).  
N(NBpp) = 173 and N(Bpp) = 12 64Bpp 830 575
Scenario 2 (i.e., real hospitalization costs) 
NBpp 1,992 3,803 Vigipneumo retrospective study in public Hospital sao paulo (Hsp).  
N(NBpp) = 173 and N(Bpp) = 12 64Bpp 5,103 6,506
Scenario 3 (including private costs and absenteeism costs)
NBpp 10,223 = 2,053 x 0.54 + 19,826 x 0.46 43,101 private costs from Vigipneumo study in albert Israelita einstein Hospital—sao paulo 
N(NBpp) = 163 and N(Bpp) = 17 were included in the societal perspective, assuming 
that around 46% of people go to private hospital 64Bpp 18,207 = 5,226 x 0.54 + 33,446 x 0.46 39,867
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hospitalized CAP in elderly (65+) in US of 1,150 cases per 
100,000. Considering that 40% on average of CAP requiring 
hospitalization are caused by S. pneumoniae,2 we estimated an 
incidence rate of hospitalized pneumococcal pneumonia of 460 
cases per 100,000. To determine the incidence of NBPP in gen-
eral, we used also the fact that 80% of pneumococcal pneumonia 
are NBPP (BPp = ¼ NBPP),2 and we used the hospitalization rates 
defined above (18.6% of NBPP + 95.5% of ¼ NBPp = 460 cases). 
We obtained 1,083 of NBPP cases per 100,000. Weycker et al. 
also recently reported an incidence of 728 NBPP cases/100,000 
in 65+ (using a mean of the moderate values weighted by popu-
lation size). Another study conducted in five European coun-
tries reported a mean incidence of hospitalized pneumonia of 
754/100,000 in elderly (65+).19 Using the same calculation as 
used by Jackson et al.5 we obtained a total NBPP incidence of 
706/100,000. Vila-Corcoles et al.37 reported an incidence of hos-
pitalized pneumonia in Spain of 1,048/100,000 in elderly (65+) 
that gave a total NBPP incidence rate of 987/100,000. The study 
from Ament et al.19 was used in the present analysis because it rep-
resents the data of five different countries. The mean European 
rate was used for the base case, and the minimum and maximum 
values (451 and 1,167 for incidence of hospitalized pneumonia 
in France and Sweden respectively) were used for the range. For 
BPP, range given by the WHO Weekly Epidemiological Record 
(WER) 2008 41 in people aged more than 65 years and leaving in 
Demographic and epidemiological model inputs. 
Representative demographic data on the São Paulo State elderly 
population was based on the national statistics data from 2007.34 
The total size of the cohort was 3,689,623. The all-cause mortal-
ity rate from São Paulo State by age group was obtained from the 
Brazilian mortality information system.35
In the base case, 18.6% was used for the probability of hos-
pitalization due to NBPP. This rate was calculated based on the 
assumption that the probability of hospitalization varies from 
10% for 60–70 years old people to 30% for people more than 
70 years old and based on the Sao Paulo population size of these 
subgroups. In the literature, the hospitalization rate related to 
CAP was reported to be 50–52.8%.7 Considering this high rate 
compared to the rest of the world where 80% of CAP patients 
are treated as outpatients, and the year of these published data, 
the value of 18.6% was selected for the analysis.36 For BPP, Vila-
Corcoles et al. (2006) found that 4.5% of IPD cases were not 
hospitalized (1/22 cases) in Spain which gives a hospitalization 
rate of 95.5%. Previous reports noted similar rates: 100% from a 
report by Sisk et al. and 96% from a study by Robinson and co-
workers. To be conservative, 95.5% was use in the base case and 
90–100% for the range (Table 2).
International pneumococcal incidence rates and case-fatal-
ity rate (CFR) were used as there were no local data available 
(Table 2). Jackson et al. (2004) reported an incidence of 
Figure 1. Model structure.
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developing countries were used. The mean value 
of the range was used in the base case analysis.
BPP CFR were retrieved from Vaccine 4th edi-
tion1 which reported a CFR range from 11% to 
44% (mean = 26.6%, 16 studies included) in 
elderly in developed countries. This range is con-
firmed by many papers: Middleton et al. (2008) 
showed a CFR of 14.3% for 65–74 years old, 21% 
in 75–84 year old and 30.8% for 85+ years old in 
US; the WHO WER of Oct 2008 reported that 
the CFR attributed to BPP may reach 30–40% in 
elderly and in industrialized countries; Evers 2007 
reported a mean CFR of 21% in 65+ among 10 
European countries. For NBPP CFR, the CFR for 
CAP was used since we could fine no relevant data 
specific to S. pneumoniae and since assuming that 
the etiology of CAP to be S. pneumoniae should 
not impact the mortality rate. In Argentina, 
a country bordering Brazil, a 18% CFR in 346 
patients with CAP (hospitalized or not) aged 18 
to 102 years (median age 64) 43 is reported and 
a 13.3% in hospitalized patients.44 Other studies 
in more industrialized countries reported a CAP-
related mortality averaged 10.7% in hospitalized 
elderly patients in US,45 3.6% in people aged more 
than 65+ (hospitalized or not) in US,5 and 12.7% 
in people aged more than 65+ in Spain.11 For the 
present analysis, a range between 3.6% and 18% 
was used for the sensitivity analysis and 12.7% 
(the more recent study-2009) in the base case.
Vaccination model inputs. For this analysis, a 
one-dose vaccination was simulated. A 60% cov-
erage rate was estimated in the case that by the 
public system and also in consideration that an 
aged-based program is easier to implement than a 
risk-based program46-48 (Table 3).
Pneumococcal vaccine effectiveness against 
IPD is the most firmly established, however the 
level of effectiveness depends on risk status and 
age. Meta-analyses of five randomized clinical 
trials have shown that PPV23 is 68% (95% CI 
53–78) effective against IPD among immuno-
competent older adults.49 In our analyses, the val-
ues for vaccine effectiveness against were based 
on multiple observational studies which had the 
advantage of being conducted in large unselected 
natural populations11,37,50-55 (Table 3). One of 
these recent studies, conducted in Scotland in 
persons aged ≥65 years, demonstrated a protective 
effect of PPV23 against IPD of 61.7% (95% CI, 
45.1–73.2).54 In Spain, a protective effect of 72% 
(95% CI, 46–95) and 70% (95% CI, 48–82) 
against IPD was reported by Vila-Corcoles et al.53 
in persons over 60 years old, and by Dominguez 
et al.53 in persons over 65. In the US, IPD vaccine 
effectiveness of 44% (95% CI, 7–67) in persons 
Figure 2. The results of the 1,000 Monte carlo simulations represented on the cost-
effectiveness plane from the three perspectives analyzed. The white dot represents the 
mean cost-effectiveness ratio. The dotted line represents a willingness to pay threshold 
of pLN 13,720/LYG (corresponding to 1 time the GDp) and the thick line a willingness to 
pay threshold of pLN 41,160/LYG (corresponding to 3 times the GDp). (a) social security 
perspective (sUs). (B) public health care perspective. (c) societal perspective.
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value given in the literature). The mean value of this range was 
used for the base case: 21% (Table 2).
In addition, as reported in various publica-
tions,11,24,37,38,41,42,53,54,56,62,63 a 10% waning rate each year was 
applied and a total duration of effectiveness was fixed conserva-
tively at 5 years (Table 2).
Vaccination costs including the vaccine public payer price 
and the door to door transportation cost, was fixed at R$27 
Brazilian reais or US$ (US$1 = R$1.7955 - mean exchange rate 
in 2008) (Table 3). In this analysis, this cost was assumed to be 
paid entirely by SUS. Adverse events costs were not included as 
they can be considered negligible. Vaccine administration costs 
for people aged over 59 years were assumed to be null since it 
was expected that vaccination would be administered during a 
regular routine visit to the general practitioner.
Cost of illness and absenteeism data. The Brazilian health 
system is divided between public and private sector. The public 
system is called SUS and is a universal system. It means that every 
Brazilian citizen has the constitutional assured right to receive 
treatment funded by the government. SUS reimbursement cover-
age is based on procedure packages that are defined in term of 
value and included services by the Ministry of Health. The fund-
ing comes from the federal, state and municipal governments. 
The private health system (HMOs, Health Plans and Health 
Insurance Companies) is financed in two ways: fully paid by the 
patient or partially covered by the patient employer. Although 
both types of health care cover the treatment of pneumonia, there 
are differences in terms of access to treatment, medications avail-
able, and cost reimbursements routes.
Information about the cost of pneumococcal infections in 
Brazil was not available in the literature. A retrospective database 
study was therefore performed in two large hospitals in Sao Paulo 
65 and older was reported by Jackson et al.55 in 2003, and 80% 
(95% CI, 51–92) in persons 65–74 years old. Shapiro et al.56 
1991 values were in accordance with the 14-year nationwide sur-
veillance study conducted by the US CDC in the elderly and in 
persons with underlying chronic disease (effectiveness of 75% in 
65+).51 As a result of these studies, effectiveness against BPP in 
the base case was assumed to be 64% for all elderly, which is the 
mean effectiveness of the observational studies. In the sensitivity 
analyses, the minimum and maximum values given in observa-
tional studies were used. These values ranged from 44% from the 
study by Jackson et al.55 to 80% from reported by Shapiro et al.
The evidence for the effectiveness of PPV23 against NBPP is 
less firmly established mainly due to the difficulties in identifying 
S. pneumoniae as etiological agent of pneumonia.49,57 However, the 
results of a recent clinical trial conducted in nursing home resi-
dents considered at high risk for CAP (mean age: 85 years) showed 
that PPV23 reduced pneumococcal pneumonia by 64% (95% CI, 
32–81) and all-cause pneumonia by 45% (95% CI, 22–61).58 A 
systematic review of observational studies,52 which may be consid-
ered to be better estimates of real-life vaccine effectiveness reported 
an effectiveness of 32% against all pneumonia. In addition, two 
recent cohort studies conducted in Spain, in which bacteria were 
identified by radiography, sputum culture, and Binex antigen 
test, demonstrated an effectiveness against NBPP of 42% (95% 
CI, 14–61) in persons >50 years old, and 39% (95% CI, -6–65) 
in elderly >65 irrespective of risk status.11,37 PPV23 has also been 
associated with reduced hospitalization of all-cause CAP by 24% 
(95% CI, 0.9–41) to 26% (95% CI, 8–41),59 lower risk of hospi-
talization and fewer deaths for pneumonia.26,60,61 Consequently in 
the current analysis, since our populations were aged ≥60 years, we 
considered a range of 0–42% effectiveness against NBPP for both 
populations in the sensitivity analyses (minimum and maximum 
Figure 3. Univariate sensitivity analysis represented on a Tornado diagram. The vertical line represents the mean IceR for the social security (sUs) 
perspective (R$7,895/LYG) and the X axis the absolute change in IceR compared to baseline.
www.landesbioscience.com Human Vaccines 1045
State to data collection: one public hos-
pital, Hospital São Paulo (HSP), and one 
private hospital, Hospital Israelita Albert 
Einstein (HIAE) were included. Both hos-
pitals are among the largest in Sao Paulo, 
each with more than 500 beds (Fig. 4).
The inclusion criteria were patients 
aged over 60 years and patients hospital-
ized for diagnosis of NBPP or BPP due 
to S. pneumoniae with a laboratory con-
firmation. In these patients, resources 
consumed were retrieved from their files. 
Theses resources included: procedures, 
laboratory tests, medical examinations, 
treatments (medications and other ther-
apies), and their length of stay in the 
intensive care unit and general ward. No 
outpatient resources were collected. As 
the cost data were not available with the 
medical records, official data sources were 
used to estimate the costs in both hospi-
tals. For the public health care setting, 
procedures, hospitalization and medical 
test costs were taken from SUS (Sistema 
Único de Saúde-Unique Health System) 
reimbursement Table,64 and devices and 
drugs costs from Ministry of Health 
prices data banking.65 Since these two 
Tables present reference values of reim-
bursement and acquisition values in the 
public health care market displaying both 
individual and combined (packages) val-
ues, two methods for building costs were 
performed. The first was from the SUS 
payer perspective and the second from 
the hospital perspective. For the private 
health care setting, Brazilian Medical 
Association Table (LPM99) was used 
for procedures, hospitalization and tests 
costs66 and SIMPRO Brazil Magazine 
(wholesales list price 2007; 2009 number 
51) for devices and drugs costs. Costs, 
expressed in Brazilian reais, were calcu-
lated and detailed in the Figure 4.
In the public hospital, two separate 
costs of hospitalization due to pneumo-
coccal infections were retrieved. These 
included; (1) the cost paid by SUS cor-
responding to the reimbursement pack-
age as defined by the Brazilian Ministry 
of Health and; (2) the total cost of hos-
pitalization corresponding to the exact 
cost for the hospital. As these two costs 
were very different (total hospitaliza-
tion costs were approximately five times 
higher than SUS costs), we decided to 
Figure 4. Results of the retrospective costs study performed in two hospitals in sao paulo. 
Figures here below present the mean hospitalization cost (in R$) per patient and pneumococ-
cal infections type in each hospital for people aged more than 59 years. (a) sUs reimbursement 
package (sao paulo hospital-Hsp). (B) Health care provider costs (sao paulo hospital-Hsp). (c) 
private costs (Israelita albert einstein Hospital-HIae).
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deterministic sensitivity analysis, 0% and 10% were used respec-
tively for the low and high value.
Conclusion
As recently described by Rijkers et al.32 pneumococcal vaccines 
may become the most important vaccines for adults and children 
worldwide in the future years. Healthcare providers and key deci-
sion makers should recognize the serious health impact of pneu-
mococcal disease in adults, closely monitor the epidemiology of 
pneumococcal serotypes, particularly ‘serotype replacement’ and 
ensure increased vaccine coverage.
Allocation of public funds is one important recognized way to 
increase the coverage rate, facilitating people’s access to vaccina-
tion. In Sao Paulo State, PPV23 vaccination program from age 
60 would be highly cost-effective considering total public hospi-
talization costs as well as the public hospitalization costs reim-
bursed by SUS. It is even likely to be cost-saving and to generate 
a return on investment when private health-care and absenteeism 
costs are considered as suggested by the present analysis. This 
paper supports therefore a universal vaccination program funded 
by the Brazilian public system.
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test the impact of these costs in two different scenarios. The 
cost difference between the SUS reimbursement and the 
total hospitalization cost represents a deficit for the public 
hospital.
In addition to these two scenarios, another one was also con-
sidered, which included the total public health care costs (not 
only the SUS reimbursement package), the private costs of hos-
pitalization, and the cost of absenteeism. Of persons over 60 
years old, 18.8% were considered active31 with a daily salary esti-
mated at R$37.59 (GDP per capita in 2007 divided by 365).14 
Absenteeism duration was considered to be equivalent to length 
of stay in hospital.
Cost of illness data was that previously presented to a Latin 
America congress.67 Table 4 shows the final costs according to 
each scenario and to the type of pneumococcal infections (NBPP 
and BPP).
Sensitivity analyses. Under base case assumptions, parameter 
values were varied individually in a one-way sensitivity analysis 
to identify which variables would have a major impact on the 
cost-effectiveness results. A variety of inputs were tested and their 
values are shown in Tables 2–4. Additional details pertaining to 
the values of the ranges are found in the epidemiological and vac-
cination inputs section.
In addition, parameters listed in Tables 2 and 3 (NBPP inci-
dence, BPP incidence, NBPP case fatality rate, BPP case fatality 
rate, vaccine effectiveness against NBPP and vaccine effective-
ness against BPP) were varied simultaneously in probabilistic 
sensitivity analyses, where random draws from each parameter’s 
distribution were performed and the effectiveness and incremen-
tal cost calculated. This procedure was repeated 1,000 times. 
Parameter distributions were chosen based on the parameter 
type and level of certainty. Those parameters whose distribu-
tions were least certain (epidemiological and case-fatality rate 
data from international literature) were assigned uniform dis-
tributions, where all values in a range are equally likely to be 
chosen. Parameters whose distributions were most certain (cost 
data from local cost of illness study) were assigned log-normal 
distributions.
A 5% discount rate on costs and lives was used in base case as 
described in the Brazilian’s health economics guidelines.68 In the 
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